MedPath

A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients

Phase 3
Completed
Conditions
Cytomegalovirus Infections
HIV Infections
Registration Number
NCT00001038
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

PRIMARY: To evaluate the efficacy of valacyclovir hydrochloride (BW 256U87) in the prevention of cytomegalovirus (CMV) end-organ disease in HIV/CMV co-infected patients with CD4+ lymphocytes \< 100 cells/mm3. To assess the impact of BW 256U87, high-dose oral acyclovir and low-dose oral acyclovir on survival.

SECONDARY: To evaluate the effect of BW 256U87 on quality of life, the safety of the drug administered concurrently with standard antiretroviral agents and other essential therapies for the treatment and prevention of opportunistic diseases, and the efficacy of BW 256U87 in suppressing activation of other herpesviruses. To evaluate serologic and virologic risk factors for the development of CMV disease, including assessment of HIV activation, and the risk of developing drug-resistant CMV, HSV, and VZV.

Gastrointestinal absorption of acyclovir is not high enough to prevent CMV disease in patients with advanced HIV disease, although there is evidence that high doses of the drug may extend survival. Valacyclovir, a prodrug that is rapidly converted to acyclovir after oral administration, has a higher absorption rate and may therefore provide inhibitory activity against CMV.

Detailed Description

Gastrointestinal absorption of acyclovir is not high enough to prevent CMV disease in patients with advanced HIV disease, although there is evidence that high doses of the drug may extend survival. Valacyclovir, a prodrug that is rapidly converted to acyclovir after oral administration, has a higher absorption rate and may therefore provide inhibitory activity against CMV.

Patients are randomized to receive BW 256U87 alone or acyclovir alone as control at either high-dose or low-dose. The acyclovir controls will provide suppressive therapy for herpes simplex infections and may affect survival.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1200
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (35)

Montreal Chest Institute

๐Ÿ‡จ๐Ÿ‡ฆ

Montreal, Quebec, Canada

Southern Alberta HIV Clinic / Foothills Hosp

๐Ÿ‡จ๐Ÿ‡ฆ

Calgary, Alberta, Canada

Yale Univ

๐Ÿ‡บ๐Ÿ‡ธ

New Haven, Connecticut, United States

Montreal Gen Hosp

๐Ÿ‡จ๐Ÿ‡ฆ

Montreal, Quebec, Canada

Medizinische Universibatspoliklinik Infekbiologie

๐Ÿ‡จ๐Ÿ‡ญ

Bern, Switzerland

CARE Ctr / UCLA Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Birmingham Veterans Administration Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Birmingham, Alabama, United States

Universita Cattolica del Sacro Cuore

๐Ÿ‡ฎ๐Ÿ‡น

Rome, Italy

Washington Univ

๐Ÿ‡บ๐Ÿ‡ธ

St Louis, Missouri, United States

Highland Gen Hosp / San Francisco Gen Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Oakland, California, United States

Indiana Univ Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Indianapolis, Indiana, United States

Universitatsklinikum Rudolf Virchow

๐Ÿ‡ฉ๐Ÿ‡ช

Berlin, Germany

Univ of California / San Diego Treatment Ctr

๐Ÿ‡บ๐Ÿ‡ธ

San Diego, California, United States

Northwestern Univ Med School

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Kaiser Permanente Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

San Francisco, California, United States

Univ of Colorado Health Sciences Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Denver, Colorado, United States

Mount Sinai Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Harvard (Massachusetts Gen Hosp)

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Ohio State Univ Hosp Clinic

๐Ÿ‡บ๐Ÿ‡ธ

Columbus, Ohio, United States

Girard Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Univ TX Galveston Med Branch

๐Ÿ‡บ๐Ÿ‡ธ

Galveston, Texas, United States

Sunnybrook Health Science Ctr

๐Ÿ‡จ๐Ÿ‡ฆ

Toronto, Ontario, Canada

Saint Vincent's Hosp Med Centre

๐Ÿ‡ฆ๐Ÿ‡บ

Sydney, Australia

Toronto Hosp

๐Ÿ‡จ๐Ÿ‡ฆ

Toronto, Ontario, Canada

Hvidovre Univ Hosp

๐Ÿ‡ฉ๐Ÿ‡ฐ

Hvidore, Denmark

South Hosp

๐Ÿ‡ธ๐Ÿ‡ช

Stockholm, Sweden

Services des Maladies Infectieuses

๐Ÿ‡ซ๐Ÿ‡ท

Paris Cedex 12, France

Univ of Washington / Madison Clinic

๐Ÿ‡บ๐Ÿ‡ธ

Seattle, Washington, United States

Westminster Hosp

๐Ÿ‡ฌ๐Ÿ‡ง

London, United Kingdom

Los Angeles County - USC Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Univ of North Carolina School of Medicine

๐Ÿ‡บ๐Ÿ‡ธ

Chapel Hill, North Carolina, United States

Royal Free Hosp

๐Ÿ‡ฌ๐Ÿ‡ง

London, United Kingdom

Johns Hopkins Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Baltimore, Maryland, United States

Boston Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

North Central Bronx Hosp / Bronx Municipal Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Bronx, New York, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath